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ABSTRACT
Background. Subjective evaluations by schizophrenic patients and their relatives of clozapine
treatment were assessed as part of an exploratory study.
Methods. A problem-centred interview was carried out with 80 patients at discharge from in-patient
or day-hospital treatment. Views of 46 relatives on the treatment were also assessed.
Results. In addition to expected effects (improvement of or stabilisation of one’s state of mental
health, antipsychotic effects), patients surprisingly often highlighted the calming and relaxing effect
of clozapine as well as improved sleep as particularly positive. While more than half of the
respondents expected a worsening of their condition if they stopped taking medication, only every
fifth patient feared a relapse. Among the negative effects, fatigue and sedation were cited by far the
most often. The absence of extrapyramidal side effects was clearly noted as an advantage of
clozapine. Only 10% of those questioned were aware of the risks for the haemotopoetic system
associated with the drug. Differences were found between patients’ and relatives’ assessments
particularly with regard to the negative effects.
Conclusions. Patients and relatives frequently hold specific and distinct views on clozapine
treatment. These views should be considered when patients and relatives are informed and when
compliance is addressed.
INTRODUCTION
Since its introduction, clozapine has been studied
in numerous clinical trials. Its efficacy, safety,
cost-effectiveness and positive effect on quality
of life are well documented (Fitton & Head,
1990; Meltzer et al. 1990, 1993; Baldessarini &
Frankenburg, 1991; Breier et al. 1994; Wagstaff
& Bryson, 1995; Morris et al. 1998). While there
is a substantial body of research on clozapine,
these studies generally use standardized quan-
titative assessment instruments, aiming at an
accurate and objective measurement of medi-
cation effects. However, their claim to objectivity
overlooks that the statements of the patients,
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which form to a large extent the basis of these
clinical studies, are by no means objective, but
subjectively influenced by reflecting the patients’
preferences and attitudes (Retzow & Emrich,
1998). To date, studies that focus explicitly on
subjective assessments of psychotropic drug
treatment have been the exception (Windgassen,
1989; Finn et al. 1990; Naber, 1995; Day et al.
1996; Angermeyer & Matschinger, 2000). There-
fore, the subjective view of those receiving the
treatment, was the specific concern of the present
study. We wanted to know what people suffering
from schizophrenia thought about neuroleptic
treatment, and especially how they perceived
treatment with clozapine. What do they like
about this medication? What is bad? In their
opinion, what are the risks associated with this
treatment? What would they expect to happen if
they stopped taking their medication? In order
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to answer these and other questions, we carried
out qualitative interviews with schizophrenic
patients. For a subsample of patients, we also
investigated their relatives’ view on clozapine.
From these statements, we subsequently hoped
to find hints as to what aspects may be of
importance for the patients’ compliance with
neuroleptic treatment.
METHOD
The study was carried out simultaneously at the
Department of Psychiatry at the University of
Go$ ttingen and at the Lower-Saxon Regional
Psychiatric Hospital in Go$ ttingen, at the Psy-
chiatric Hospital ‘Philippshospital ’ in Riedstadt
and at the Department of Social Psychiatry at
the Free University Berlin. The four hospitals
were chosen with the aim of including a wide
spectrum of patients with regard to treatment
setting (university hospital v. state hospital) and
place of residence (urban v. rural). All schizo-
phrenic patients (ICD-9, 295) between 18 and 60
years of age who had been treated with clozapine
during their in-patient or acute day-hospital
treatment and were discharged with the recom-
mendation to continue this medication on an
out-patient basis were included in the study. In
total, 104 patients consecutively discharged from
the four hospitals participated. At discharge
from hospital, the ‘Interview on Subjective
Illness Theory’ (Holzinger et al. 2001) was
carried out with the patients.
The ‘Interview on Subjective Illness Theory’
is a problem-centred interview (Witzel, 1985).
This form of interview is similar to the focused
interview developed by Merton & Kendall
(1945}46). The semi-structured interview is de-
signed in such a way as to give respondents the
opportunity to freely articulate their views, i.e. it
is intended to bear the maximum possible resem-
blance to an open conversation. However, it
focuses on a particular problem introduced and
continuously probed for by the interviewer. An
interview guide was developed specially for the
interview, which addresses the essential aspects
of subjective illness theory (labelling, causal
attributions, perceptions of prognosis, control
attributions). In connection with this, we also
assessed respondents’ views on the treatment
they receive, including specific questions on
clozapine treatment. We posed the following
introductory question: ‘You are taking Clozaril
at the moment. How do you feel about it? ’.
Further questions were ‘What, do you think,
would change if you were to stop taking this
medication?’ and ‘Do you think that taking
Clozaril for longer periods of time could lead to
problems of any sort? ’. Finally, patients were
asked to compare their current medication with
the one they had received previously: ‘Earlier
you also took other medications. Is there any
difference between Clozaril and the drugs you
took before? ’. The same questions, phrased
slightly differently, were also posed to the
relatives. Interviews tookbetween 35 and 55 min.
Theywere tape-recordedand subsequently trans-
cribed.
The full set of transcripts was analysed by
means of structuring qualitative content analysis
(Mayring, 1990). The method simultaneously
allows the analysis of subjective concepts and
the identification of structures in the qualitative
material. It was designed to facilitate the
combination of qualitative methods with stat-
istical analysis. Hence, it was particularly suited
for our study, which aimed at assessing both
subjective evaluations and the frequency and
distribution of the judgments made. In a first
step, texts were divided into blocks based on
units of meaning. Blocks were then given a code,
which was formulated on the basis of the original
formulations of the respondents (paraphrasing).
Paraphrases subsequently served as the basis for
the formation of categories, which was carried
out by means of an inductive method, i.e. new
categories were formed and constantly revised
until all relevant information from the interview
transcripts was included. Coding was done
independently by two researchers. Results were
compared by an interdisciplinary research team
consisting of psychiatrists and psychologists.
The team resolved possible discrepancies and
summarized similar codes in generic categories
until the final coding system was arrived at.
For content analysis, a computer-based ap-
proach was chosen, using the software package
WinMax (Kuckartz, 1988). The program allows
simultaneous access to the texts analysed, the
coded blocks of text and the categories of the
coding system relevant for the respective trans-
cripts. It is further designed to facilitate the
‘quantification’ of verbal data by defining
variables from the categories and reading them
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into a statistics package without losing reference
to the original data. In our study, data collected
through the inductive procedure was thus con-
verted into an SPSS file for statistical analysis.
Frequency counts were carried out for the
number of mentions in each category. The
McNemar test was used to analyse whether
there were statistically significant differences
between the patient’s views of clozapine treat-
ment and those of their relatives.
In total, analysable transcripts of the interview
were available for 80 patients. Of the 104 patients
originally recruited, 18 did not give their
agreement with taping the interview. In six
cases, the quality of the tape recording was too
poor to allow transcription. Of the remaining 80
patients, 60% were male. One-third of the
sample was: under 30; between 30 and 40; and
over 40 years of age. Seventy-four per cent of the
sample was single, 37–5% lived on their own,
20% lived with their parents and 17–5% with
their spouses or partners. With regard to
education: 32–5% of the respondents had com-
pleted secondary school below O-Levels ; 32–5%
had done O-Levels ; and 26% had done A-
Levels. Among the sub-types of schizophrenia,
the paranoid type (ICD-9, 295.3) was most
frequently represented at 42–5%. On average,
patients had been admitted to in-patient treat-
ment on five previous occasions. The median
length of cumulative stay at the hospital was 15
months. At the time of the interview, patients
displayed fewer positive symptoms and about as
many negative symptoms as the representative
sample of first admitted schizophrenic patients
studied in the ABC project (Ha$ fner et al. 1992).
Before being switched to clozapine, patients had
been treated with up to 13 different traditional
neuroleptics (medianfl 4). On average, patients
had been on clozapine for almost 3 years (Table
1).
At one site (Go$ ttingen), 38 patients were
questioned using the ‘Interview on Subjective
Illness Theory’ and again 6 months after
discharge. For 46 patients, we also investigated
their closest relatives ’ attitude to clozapine
treatment. Eighteen patients did not have close
friends or relatives. In nine cases, patients
objected against their relatives being inter-
viewed, in seven cases the relatives declined to
participate in the study. Forty-one per cent of
the relatives questioned were parents (in most
Table 1. Clinical characteristics
% Median Range
CATEGO syndrome
Nuclear syndromes 51–9
Auditory hallucinations 29–6
Delusions of persecution 25–9
Delusions of reference 27–2
Residual syndrome 27–2
Affective flattening 30–9
Slowness 43–2
Lack of energy 50–6
Simple depression 76–5
Incoherent speech 2–5
Number of previous
hospital admissions
5 1–28
Duration of previous
hospital admissions (months)
15 1–143
Number of previously
prescribed neuroleptics
4 1–13
Length of time on clozapine
(months)
34 1–96
cases mothers), 20–8% were spouses or partners,
4–1% were the patients’ brothers or sisters and
33–4% were other persons.
RESULTS
Positive effects of clozapine treatment
Most frequently – in almost one-third of the
cases – patients generally stated that they felt
better as a result of clozapine. The degree of
improvement varied between ‘a bit ’, ‘ in-
creasingly’ and ‘considerably’ (Table 2). For
example one patient said: ‘I mean, in retrospect,
I feel better, so I guess it must have been the
right treatment’. Patients felt helped by the
medication and comparatively well. Some
patients (5%) spoke of a stabilization: ‘I feel
more stable now, not so weak anymore’. In only
a few cases, patients mentioned that they were
fully recovered thanks to the treatment: ‘Now I
feel just as well as I used to when I was healthy’.
With striking frequency, a favourable influence
of clozapine on sleeping patterns was
emphasized. Twenty-five per cent of the
respondents mentioned this beneficial effect.
Clozapine would help patients to sleep: one
could sleep ‘well ’, ‘calmly’, ‘deeply’, and even
‘fantastically ’. One patient stated in this regard:
‘Well, I would say, it’s a bit of a sleeping pill,
perhaps, ‘cause I always sleep through the
night ’. Just as frequently, clozapine’s calming
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Table 2. Assessment of clozapine treatment by
patients
%
Positive effects
Overall improvement 30–0
Improved sleep 27–5
Calming effect 27–5
Antipsychotic effect 18–7
Antidepressant effect 11–2
Anxiolytic effect 7–5
Improved functioning 7–5
Recovery 5–0
Stabilization 5–0
Reduction of cognitive deficits 5–0
Protection}distance 3–7
No statement 16–2
Negative effects
Fatigue}sedation 56–2
Lack of motivation 21–2
Hypersalivation 21–2
Anticholinergic effects 16–2
Weight gain 15–0
Orthostatic hypotension 11–2
Cognitive deficits 11–2
Restlessness 5–0
Increased perspiration 5–0
Sexual dysfunction 5–0
Akathisia 3–7
Headaches 3–7
Other 12–5
No statement 13–7
Comparison with traditional neuroleptics
No parkinsonism 27–5
No akathisia 12–5
No acute dystonia 12–5
No restlessness 11–2
Reduced sedation 8–7
Reduced cognitive deficits 3–7
Other 16–2
No statement 32–5
effect was highlighted. Taking the drug, one
would feel calmer, more relaxed, more balanced:
‘Clozaril is also calming…I mean there’s a kind
of substance in it…some sort of a salt or
something…or some sort of substance, you
know, that makes the nerves work more
slowly…or something … Well, I ’m not a doc-
tor… ’ Another patient explained the calming
effect as ‘a blockage of brain functions ’. When
asking about the positive effects of clozapine, its
antipsychotic effect was mentioned compara-
tively rarely. Among these statements, it was
most frequently remarked that the drug caused
the voices to become fainter, that the latter were
only present in the evening or ‘upon request ’, or
that they had disappeared completely. One
patient was very satisfied: ‘I don’t see a chance
for the voices. Yes, this is the only drug that
managed to get rid of the voices ’. In addition,
almost every tenth patient noticed an anti-
depressant effect. Clozapine was identified as
leading to a brighter mood: ‘When I’m rather
down and then take these tablets…well, that
helps me all right ’. An anxiolytic effect was
mentioned slightly less frequently : ‘The anxieties
are less present ’. Some patients also stressed the
positive influence on their ability to work and to
successfully manage their daily lives. One patient
ascribed to the medicine that ‘I can spend 8
hours at the university without any problems…I
can go in for sports and things like that like
everybody else…without any restrictions ’.
Another group of patients considered the medi-
cation as a protection from the illness. In
accordance with the stress–vulnerability con-
cept, one patient argued: ‘And I’ve got the
impression, that the stuff shields me…that it
shields my soul… because I’m not very well
protected, and this medicine, Clozaril, is more
capable of giving my soul some protection’. A
second patient also conveyed this effect :
‘Therefore it does help…well, because I don’t
experience these irritations as forcefully
anymore… ‘cause I am a little shielded’.
Expected consequences of a discontinuation of
clozapine treatment
A further aspect, which is revealing with regard
to the evaluation of the positive effects of a drug,
is the answer to the question as to what would
happen if one stopped taking it. Almost half
(43–7%) of the respondents expected a worsening
of their mental state in that case. Twenty per
cent of those questioned expressed the fear they
would ‘become ill once again’. According to the
patients’ judgement, the ‘possibility of a relapse
would be quite large’. For another patient it was
certain that ‘If I didn’t take it, the psychosis
would rule again’. One patient expressed that
the reappearance of the psychosis would be ‘a
real catastrophe’. A further patient spoke from
experience: ‘When I leave that out, the skies fall
upon me’. In view of the above-mentioned
positive effects of clozapine on the quality of
sleep it is not surprising that 10% of patients
expected insomnia if they stopped taking the
medication. Five per cent of those questioned
feared they would become more restless, irritable
and ‘exited}nervous}flustered’ again. The op-
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posite case, i.e. that some patients anticipated an
improvement in their condition, was compara-
tively rare – only 7–5% anticipated such a
development. For example, one patient believed
that ‘without medication, I am able to think
better…clearer, able to work better, go out
more in the evenings, go for walks’. Even less
frequently (in 5% of the cases), patients believed
that whether or not they take the psychotropic
drug was irrelevant to their well-being. Thirty-
five per cent of the respondents were incapable
of making a statement in this regard, 12–5%
answered this question with ‘I don’t know’.
Negative effects of treatment with clozapine
While respondents on the one hand welcomed
the calming effect of clozapine, they also
complained about the sedating effect of the drug
(Table 2). More than half of those questioned
considered this to be a disadvantage of clozapine.
Fatigue}sleepiness was mentioned most fre-
quently – a side effect that apparently caused
particular trouble to patients at the beginning of
treatment: ‘I was terribly sleepy upon taking the
medication’. Besides patients felt muted, worn-
out, even dazed and numbed. As one patient
complained: ‘…yes, it just dampens quite
strongly…yes, when the dosage was somewhat
higher, I felt rather gooey’. About one-fifth of
the respondents attributed the lack of motivation
they felt to the treatment with clozapine. In most
cases, the latter manifested itself in the patients’
difficulty getting up in the morning: ‘It is really
difficult to get up then, to get out of bed…which
was easier for me before ’. In addition, patients
complained of passivity, lethargy, and a lack of
enthusiasm and interest : ‘…yes, that I’m
unmotivated…before I got ill I read a lot and
dealt with intellectual things, and today I don’t
do these things anymore… it’s relatively rare
that I still read something’. For a further fifth of
the patients, hypersalivation was an aggravating
concomitant of the medication: ‘When I wake
up, there’s always this stain in my bed from
slobbering’. However, according to one patient’s
view, this disadvantage is offset by clozapine’s
positive effect : ‘ It’s true, I’ve got salivation
through it, but at least it allows me to sleep for
a few hours’. Every sixth respondent reported
anticholinergic effects, in which constipation
was the most frequent complaint (‘you have to
take laxatives with that stuff’). Similarly often,
patients complained about weight gain: ‘…and
I mean, this is a point, of course, that isn’t so
nice with the medication, when you go swimming
then somebody says: ‘MyGod, have you become
fat ! ’ ‘…and you put on something like 10 kilos
in 2 weeks, and then you get this tension in your
belly, as if you were about to burst… ’. Another
patient took it with a sense of humour: ‘I don’t
really know how it functions…but the people
who take Clozaril like myself, they’ve all put on
weight…they’ve become corpulent…but I’d
rather be fat and clear-headed… ’. Every tenth
respondent complained about orthostatic hy-
potension, above all about dizziness : ‘Under
that Clozaril, that I was given, I simply couldn’t
work…I stood on the ladder and then I got
dizzy’. Just as frequently, cognitive deficits were
cited as a negative consequence of clozapine
medication. Here, it was particularly poor
concentration which patients reported: ‘… yes,
it’s very difficult to concentrate, to focus on
something… ’. The following negative effects of
the medication were mentioned comparatively
rarely – by a maximum 5% of the respondents :
sexual dysfunction, increased perspiration, head-
aches, akathisia and, as put by the patients, a
more general feeling of ‘restlessness ’.
Risks of long-term treatment with clozapine
When asked about the potential risks of long-
term treatment with clozapine almost every
third respondent did not know what to answer.
Almost one patient in four denied that this drug
may be accompanied by any risks. While one in
ten was aware of the risk of damage to the
haemotopoetic system: ‘This change in the blood
count cannot be precluded…one doesn’t really
know…the odd person gets it, and even if it is
just with 1%, that’s bad enough’. Only one
patient could spell out in more detail what kind
of a change in the blood count might be caused
by clozapine, but he was not too sure either :
‘…well, there’s this thing with the…with the
leukocytes…that’s what you call them, isn’t
it?… that this is not such a good thing,
perhaps…I mean, blood is among the most
important things that man has, you see’. With
the same frequency, patients expressed the fear
of becoming addicted to the drug: ‘Yes, I won’t
be able to live without these tablets anymore at
all. I’m addicted to them, one could nearly say,
yes, dependent on them’. Every tenth respondent
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anticipated the possibility that the treatment
with psychotropic drugs might cause damage to
inner organs, especially to the liver.
Comparison of clozapine with traditional
neuroleptic drugs
As compared with conventional neuroleptics,
patients clearly preferred clozapine (Table 2).
Every second respondent criticized the
extrapyramidal-motor side effects of the tra-
ditional neuroleptics, in particular haloperidol,
or stressed their absence as an advantage of
clozapine. Most frequently, patients described
symptoms of parkinsonism: tremor (‘I already
had the shakes or something… in the past…but
I don’t get this anymore now… ’, ‘rigidity
(‘… these drugs totally destroy you…make you
unable to move and stiff all over…you can’t
speak anymore…this doesn’t happen with
Clozaril ’, or : ‘ I thought I was made out of
concrete or something…I could hardly move
when I took that stuff’ ; and akinesia
(‘Haloperidol was probably stronger…so that
some things were…when you moved, it felt like
being a robot, that you’re just totally slowed
down and things, in walking, speaking, and in
feeling’. One patient was infuriated about the
side effects : ‘Let me tell you one thing:
haloperidol is the last piece of shit…you walk
around like a robot, and I find it very doubtful
that drugs like this are being prescribed at
all…I mean I would ban them immediately if I
had the power to do that ! ’. On the other hand,
the absence of akathisia is cited as an advantage
of clozapine: ‘With Clozaril…you can sit still ’.
By contrast being on haloperidol was described
as follows: ‘I wasn’t even able to sit down at the
table and have my dinner. Yes, it’s such a
complete inner restlessness that keeps bothering
you…I never walked as much in my life as I did
then’. Patients also had unpleasant memories of
acute dystonia, which had occurred during
treatment with conventional neuroleptics. As
one patient reported: ‘I was given haloperidol,
and then I got eye cramps. I couldn’t walk
anymore, couldn’t wash myself anymore, was
unable to eat without assistance, couldn’t speak
anymore. I had throat cramps, too, and an
awful lot of salivation. And when I came home
from the hospital, they told me: ‘‘When you eat
and drink like that you might as well have your
dinner down in the cellar ’’.’
Evaluation of clozapine 6 months after
discharge from hospital
As described in the method section, we re-
interviewed a subsample of patients 6 months
later. The evaluation of clozapine was virtually
identical with the results at discharge from
hospital. This applies to the positive and the
negative effects as well as to the assessment of
the possible risk of long-term treatment with
this drug. Only patients’ awareness of the risk
that their condition might deteriorate when they
stopped taking their medication was even more
pronounced than previously (55–3% as com-
pared to 42–1%). The results of the comparison
between clozapine and other neuroleptics, how-
ever, remained unchanged: patients clearly
favoured clozapine.
Comparison with the relatives’ view
As mentioned before, for 46 patients, interviews
with their closest relatives were also available. In
the following, we will point out differences
between the two, which, using McNemar’s test,
reach statistical significance (P! 0–05). If one
compares the assessment of the positive effects
by the relatives with that by the patients, no
significant differences can be found. For both,
the general improvement of the patients’ con-
dition and the calming effect were the most
important desirable effects of clozapine treat-
ment. There are obvious differences regarding
patients’ and relatives’ judgements on the poss-
ible consequences of a discontinuation of taking
the medication. Most strikingly, only one-third
of the relatives did not know what would happen
if patients stopped taking their medication, while
it was nearly two-thirds of the patients who had
no answer to this question. Most frequently,
relatives expected a deterioration in the patients’
condition. By contrast, only one-third of the
patients feared such a development. The as-
sessment of the negative effects of clozapine
treatment revealed that weight gain was less
frequently identified as a negative effect of
clozapine by the patients than by their relatives.
The opposite is true for those side effects, which
are not directly visible, but may considerably
affect patients’ well-being and functioning:
hypersalivation and the anticholinergic side
effects (above all constipation and disturbance
of accommodation) are the most frequently
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cited undesirable effects in this regard. The latter
were hardly noticed by the relatives while they
were frequently perceived as a problem by
patients. The possibility of damage to inner
organs was the most central concern of relatives
with regard to the risks of clozapine treatment.
Almost every third relative considered it as a
possible consequence of taking the medication.
By contrast, about every tenth patient was
concerned about the risk of organ damage. Like
the patients, the relatives also noted a number of
advantages of clozapine over traditional neuro-
leptics. They also recognized that clozapine does
not lead to extrapyramidal side effects – or does
so to a lesser extent – which are known to occur
in conjunction with traditional psychotropic
drug treatment. Relatives further highlighted
the reduction of inner unrest, that accompanied
the older drugs, as an advantage of clozapine.
Some relatives were also pleased with the fact
that patients were less sedated than with previous
medication. Further, the absence of akathisia
and cognitive deficits with clozapine treatment
were stressed as an improvement by the relatives.
DISCUSSION
The fact that patients, relatives and mental
health professionals can differ considerably in
their evaluation of the various positive and
negative effects of clozapine treatment is perhaps
the most important finding of our study. While
psychiatrists prescribe the medication with the
aim of reducing psychotic symptoms or pre-
venting relapse, patients stressed the calming
and relaxing effect as well as the improvement in
sleep as a positive effect of clozapine. On the
other hand, the drug’s antipsychotic effect was
mentioned comparatively rarely – which is all
the more remarkable as the patients in this study
had just experienced an exacerbation of their
psychosis. One gets the impression that a
significant proportion of the patients viewed
clozapine more as a tranquilizer or a sleeping
pill than an antipsychotic drug. This and the
antidepressant effect reported by individual
patients suggest that the medication’s immediate
effect may be most significant for how patients
assess the drug. The – already achieved –
reduction of acute psychotic symptomatology
and the prevention of relapse seem to be less
important for the patients’ view of clozapine.
While psychiatrists are aware of the risk of
agranulocytosis and thus carry out regular white
blood cell counts, the patients were not very
aware of the risks associated with clozapine
treatment. Only every tenth patient had a notion
of the possible effects of clozapine on the
haemopoetic system, a notion that was generally
very vague. With the same frequency, patients
expressed the fear that they might become
dependent on clozapine. In Germany, as in
many other countries, the provision of extensive
and precise information to the patients about
the risk of agranulocytosis is a special formal
requirement for clozapine treatment. Moreover,
patients are regularly reminded of that risk
when they undergo frequent blood monitoring.
Nevertheless, 90% did not mention it when
interviewed in this study. One can only speculate
about the reasons. Patients might deny a serious
risk that is beyond their influence and avoid
facing it. The risk may be very theoretical and –
despite all the medical information – difficult to
understand. And a mere risk with a low
probability of occurring might appear of little
relevance in the light of many other more
immediate real problems.
Differences are also evident between patients’
and relatives’ judgements on clozapine treat-
ment. This is particularly true for the undesired
effects, in which their visibility seems to play a
major part. While patients more frequently
complained of hypersalivation and anti-
cholinergic side effects, which remain largely
hidden from others, relatives more frequently
were unhappy about the patients’ apparent
weight gain. In addition, relatives are even more
aware than patients of the risk of relapse if
clozapine medication is discontinued. On one
issue, however, there is agreement between
patients and relatives : both state the advantages
of clozapine in comparison with conventional
neuroleptics. There was unmistakable relief
about the fact that patients are no longer plagued
by the symptoms of parkinsonism, akathisia or
acute dystonia. It is plausible to conclude that
this positively affects compliance.
The results reported herein are of particular
relevance for clinical practice. Our findings point
to the necessity for psychiatrists to explore
patients’ subjective views and motivations with
regard to their medication in order to improve
treatment adherence. It may further be con-
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cluded that patient information and relative
information should be specific and in some
respects different. Appropriate information for
patients should not be dominated by the
agranulocytosis risk only, and may have to
focus more on the antipsychotic effect. The
potentially positive sedative effects are to be
explicitly addressed. Discussions with relatives
should especially address an adequate under-
standing of weight gain. Moreover, the range of
views expressed within each group, i.e. patients
and relatives, underlines the importance of a
detailed assessment of individual concerns and
perceived effects when addressing compliance
issues.
With regard to the comparison between
perceptionsof clozapineandconventionalneuro-
leptic drugs, our finding may be prone to a
selection effect as those patients receiving this
drug are likely to have found traditional neuro-
leptics unacceptable or of limited help. Through
independent coding and multiple professional
perspectives in the research team, it was
attempted to minimize bias implicit in the
analysis of qualitative data.
Based on a qualitative methodology, the
present results are limited in terms of
generalizability. However, the method was
chosen for a specific purpose: the exploration of
the subjective meanings patients associate with
the treatment they receive. Knowledge of how
patients – and relatives – think and speak about
medication effects supplement the picture pro-
vided by clinical rating scales and may help to
understand the motivations for compliance. In
this regard, the present study can only be of an
explorative nature. More detailed qualitative
research is necessary for obtaining a more
comprehensive and accurate understanding. On
the other hand, our results could serve as the
basis for developing a more standardized in-
strument to measure patients’ and relatives’
assessment of neuroleptic treatment.
This study is an example of how important
subjective views, gathered using qualitative
techniques may be quantified and subjected to
statistical analysis. The method lends itself to
more widespread use and could be incorporated
into large scale outcome studies. In randomised
controlled trials evaluating neuroleptic treat-
ment regimes patients’ and relatives’ views might
be assessed as outcome criteria in addition to
using established quantitative scales. Fre-
quencies of specific positive and negative state-
ments about the treatments in question can be
analysed, and differences between groups may
be tested for statistical significance. This ap-
proach for capturing subjective outcome might
be regarded as an alternative to conventional
rating scales assessing patients’ treatment sat-
isfaction, self-rated side effects, and self-rated
symptom change. Similar methods might also
prove beneficial in evaluating patients’ and
relatives’ views on types of psychiatric treatment
other than atypical neuroleptics.
We thank the reviewers for their comments on an
earlier draft of this paper.
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